Dengue fever
Conditions
Interventions
Experimental group:Symptomatic treatment+Chai-shi-Jie-Du granules
Placebo group:Symptomatic treatment+Placebo of Chai-shi-Jie-Du granules
Sponsors
Guangzhou Eighth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. All cases of dengue fever (acute febrile phase) that meet the diagnostic criteria; 2. Individuals (or their guardians) who agree to participate in a randomized controlled trial and sign an informed consent form; 3. Body temperature >38°C, with symptom onset time =3 days; 4. Age: 18-65 years old; 5. Primary symptoms include fever, chills, red tongue, thick or greasy tongue coating, and soft, slippery, and rapid pulse; belonging to the pattern of damp-heat stagnation with simultaneous involvement of defensive and nutrient qi.
Exclusion criteria
Exclusion criteria: 1. Patients with concomitant bacterial infections; 2. Patients with viral hepatitis (excluding viral carriers), post-hepatitic cirrhosis, HIV/AIDS, or other acute infectious diseases; 3. Patients with concomitant hematological disorders; 4. Patients with immune-mediated diseases such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, psoriasis, or inflammatory bowel disease; 5. Patients with severe underlying diseases or conditions deemed unsuitable for trial participation by investigators (e.g., severe respiratory diseases, cirrhosis, malignant tumors, chronic congestive heart failure, chronic renal insufficiency/history of hemodialysis, cardiovascular/cerebrovascular diseases, or severe psychiatric disorders); 6. Patients presenting with any of the following clinical manifestations: severe abdominal pain, persistent vomiting, chest tightness/palpitations, lethargy/agitation, significant bleeding tendency (mucosal bleeding or extensive skin ecchymosis), arrhythmia, pleural effusion, ascites, or deep jaundice; 7. Pregnancy or suspected pregnancy (pregnancy testing required prior to enrollment; pregnant patients excluded); 8. Patients with severe dengue (e.g., severe bleeding, altered consciousness, or shock); 9. Patients with suspected hypersensitivity to the investigational drug or concurrent participation in another clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Defervescence time;Platelet recovery time;Complication Incidence Rate;Critical conversion rate;Time and degree of viral load reduction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to Symptom Relief or Resolution;Adverse Reactions and Adverse Events; | — |
Countries
China
Contacts
Public ContactXinghua Tan
Artemisinin Research Center,Guangzhou University of Chinese Medicine
Outcome results
None listed